Stock Track | Harrow Health Plunges 13.25% Post-Market on Earnings Miss and Weak 2026 Guidance
Stock Track
Mar 03
Harrow Health Inc. (HROW) experienced a significant post-market plunge of 13.25% on Monday.
The sharp decline followed the company's release of its fourth-quarter 2025 financial results, which revealed earnings that fell significantly short of analyst expectations. Harrow reported Q4 earnings per share of $0.17, missing the FactSet consensus estimate of $0.37 by a wide margin.
Adding to investor concerns, the company issued its 2026 revenue guidance in the range of $350 million to $365 million, which is substantially below the analyst consensus expectation of approximately $386 million to $391 million. This combination of an earnings miss and weaker-than-anticipated forward outlook prompted the post-market selloff.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.